MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-04-2025
Glaukos Corporation Operating Income 2011-2026 | GKOS
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Glaukos Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -129 M | -82.3 M | -32.9 M | -124 M | -50.3 M | -13 M | -2.28 M | 4.24 M | -10.3 M | -13.2 M | -14.2 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.24 M | -129 M | -42.4 M |
Quarterly Operating Income Glaukos Corporation
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22.7 M | -20.7 M | - | -30 M | -39.1 M | - | -28 M | -29.1 M | -33 M | - | -21.6 M | -36.8 M | 9.79 M | -17.9 M | 11 M | -14.2 M | -11.8 M | -11.4 M | -12.4 M | -47.2 M | -52.6 M | -29.7 M | -12.4 M | -6.24 M | -1.94 M | 1.9 M | -6.94 M | -4.25 M | -3.71 M | 532 K | 748 K | -3.86 M | 304 K | 468 K | 1.03 M | 2.12 M | 621 K | -2 M | -1.72 M | -5.38 M | -1.18 M | -5.02 M | -1.88 M | -2.24 M | -4.03 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11 M | -52.6 M | -11.7 M |
Operating Income of other stocks in the Medical instruments industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
22.6 K | - | - | $ 810 M |  USA |
 |
Becton, Dickinson and Company
BDX
|
2.58 B | $ 154.51 | -1.17 % | $ 44.4 B | USA |
 |
Repligen Corporation
RGEN
|
47.7 M | $ 117.78 | -0.46 % | $ 6.56 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
-13.3 M | $ 9.4 | -11.74 % | $ 22.8 M | USA |
 |
Haemonetics Corporation
HAE
|
222 M | $ 56.83 | 1.05 % | $ 2.86 B | USA |
 |
ICU Medical
ICUI
|
42.8 M | $ 123.31 | -1.53 % | $ 3.04 B | USA |
 |
Intuitive Surgical
ISRG
|
2.95 B | $ 452.07 | -2.67 % | $ 161 B | USA |
 |
Harvard Bioscience
HBIO
|
-48.6 M | $ 5.2 | 2.16 % | $ 231 M | USA |
 |
Isoray
ISR
|
-114 M | - | 0.03 % | $ 108 M | USA |
 |
AngioDynamics
ANGO
|
-40 M | $ 10.31 | -13.65 % | $ 421 M | USA |
 |
Repro Med Systems
KRMD
|
-2.97 M | $ 4.32 | 1.17 % | $ 200 M | USA |
 |
AtriCure
ATRC
|
-9.45 M | $ 29.07 | 2.68 % | $ 1.39 B | USA |
 |
Pulse Biosciences
PLSE
|
-76.9 M | $ 23.0 | -0.13 % | $ 1.55 B | USA |
 |
InfuSystem Holdings
INFU
|
1.65 M | $ 9.29 | -0.11 % | $ 192 M | USA |
 |
Masimo Corporation
MASI
|
-267 M | $ 178.59 | 0.33 % | $ 9.52 B | USA |
 |
iRhythm Technologies
IRTC
|
-57.4 M | $ 116.8 | -1.2 % | $ 3.74 B | USA |
 |
Merit Medical Systems
MMSI
|
185 M | $ 67.7 | -0.78 % | $ 4 B | USA |
 |
BioLife Solutions
BLFS
|
-7.13 M | $ 19.51 | 1.14 % | $ 899 M | USA |
 |
electroCore
ECOR
|
-13.2 M | $ 6.8 | 3.03 % | $ 57.7 K | USA |
 |
STERIS plc
STE
|
867 M | $ 218.71 | -0.56 % | $ 21.6 B | USA |
 |
Teleflex Incorporated
TFX
|
13.9 M | $ 117.81 | -0.52 % | $ 5.26 B | USA |
 |
Utah Medical Products
UTMD
|
11.4 M | $ 63.12 | 0.4 % | $ 205 M | USA |
 |
OraSure Technologies
OSUR
|
-72 M | $ 3.08 | 0.98 % | $ 226 M | USA |
 |
West Pharmaceutical Services
WST
|
585 M | $ 254.8 | 0.82 % | $ 18.4 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
-422 M | $ 11.63 | -0.26 % | $ 2.32 B | USA |
 |
ResMed
RMD
|
1 B | $ 224.09 | 0.56 % | $ 32.7 B | USA |
 |
Predictive Oncology
POAI
|
-181 M | - | - | $ 31.1 M | USA |
 |
Baxter International
BAX
|
-308 M | $ 16.68 | -0.6 % | $ 8.56 B | USA |
 |
NeuroMetrix
NURO
|
-8.78 M | - | 5.05 % | $ 9.02 M | USA |
 |
STAAR Surgical Company
STAA
|
-91.7 M | $ 20.21 | 4.55 % | $ 1 B | USA |
 |
Stereotaxis
STXS
|
-22.1 M | $ 1.87 | 1.08 % | $ 170 M | USA |
 |
The Cooper Companies
COO
|
683 M | $ 70.17 | -1.76 % | $ 14 B | USA |
 |
LeMaitre Vascular
LMAT
|
67.9 M | $ 108.49 | -0.24 % | $ 2.46 B | USA |
 |
Microbot Medical
MBOT
|
-14.7 M | $ 2.4 | 1.27 % | $ 110 M |  Israel |
 |
Nephros
NEPH
|
-1.59 M | $ 2.87 | -2.21 % | $ 29.8 M | USA |
 |
Envista Holdings Corporation
NVST
|
216 M | $ 25.81 | -0.35 % | $ 4.34 B | USA |
 |
Milestone Scientific
MLSS
|
-5.7 M | $ 0.28 | -4.86 % | $ 23 M | USA |
 |
Alcon
ALC
|
580 M | $ 74.56 | -1.26 % | $ 40.4 B |  Schweiz |
 |
Pro-Dex
PDEX
|
10.7 M | $ 51.67 | 1.33 % | $ 170 M | USA |
 |
Retractable Technologies
RVP
|
-21.2 M | $ 0.69 | 2.99 % | $ 20.7 M | USA |